Released Nov 8, 2023, after the close
10-Q filed Nov 8, 2023, 39 days after period end · 0000950170-23-061148
Q3 2023 · 10-Q
Revenue$184.01M$184.01M +61.4% vs Q3 2022−1.6% vs Q2 2023
Net Income-$28.86M-$28.86M N/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.77-$0.77 N/M vs Q3 2022N/M vs Q2 2023
Gross Profit$119,763,000+43.6%
Operating Income-$24,449,000N/M
Operating Cash Flowderived$477,000N/M
Free Cash Flowderived-$21,395,000N/M
Margins · derived
Gross margin65.1%−8.1 pt vs Q3 2022
Operating margin-13.3%−8.2 pt vs Q3 2022
Net margin-15.7%−6.3 pt vs Q3 2022
What the release said
The release
Same quarter
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Revenue | $184.01M | $114.00M | $112.43M | $110.99M |
| Net Income | -$28.86M | -$10.72M | -$2.17M | $4.65M |
| EPS Diluted | -$0.77 | -$0.53 | $0.11 | $0.24 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR